GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Cash, Cash Equivalents, Marketable Securities

Q BioMed (Q BioMed) Cash, Cash Equivalents, Marketable Securities : $0.02 Mil (As of Feb. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Cash, Cash Equivalents, Marketable Securities?

Q BioMed's quarterly cash, cash equivalents, marketable securities declined from Aug. 2022 ($0.14 Mil) to Nov. 2022 ($0.05 Mil) but then stayed the same from Nov. 2022 ($0.05 Mil) to Feb. 2023 ($0.02 Mil).

Q BioMed's annual cash, cash equivalents, marketable securities increased from Nov. 2020 ($0.18 Mil) to Nov. 2021 ($0.34 Mil) but then declined from Nov. 2021 ($0.34 Mil) to Nov. 2022 ($0.05 Mil).


Q BioMed Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Q BioMed's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Cash, Cash Equivalents, Marketable Securities Chart

Q BioMed Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.68 0.17 0.18 0.34 0.05

Q BioMed Quarterly Data
May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.03 0.14 0.05 0.02

Q BioMed Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Q BioMed  (OTCPK:QBIO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Q BioMed Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Q BioMed's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Q BioMed (Q BioMed) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Executives
William S Rosenstadt director, 10 percent owner, officer: Chief Legal Officer ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin director, 10 percent owner, officer: Chief Executive Officer 10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci director 501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay 10 percent owner 580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1